ABEO
ABEO clinical trials: ABEONA THERAPEUTICS INC.
Every trial on ClinicalTrials.gov where ABEONA THERAPEUTICS INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 13
- Trials linked
- 11
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ABEO on the catalyst calendar · ABEO registry changes
- Primary completion Nov 2031Sponsor estimatePhase 4NCT07717736Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of WoundsAbeona Therapeutics, Inc · Epidermolysis Bullosa (EB)Not yet recruitingABEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2036Sponsor estimateNo phase registeredNCT05708677A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEBAbeona Therapeutics, Inc · RDEBEnrolling by invitationABEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2045Sponsor estimateNo phase registeredNCT07700966A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic...Abeona Therapeutics, Inc · Recessive Dystrophic Epidermolysis BullosaRecruitingABEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2025Sponsor estimatePhase 3NCT05725018A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated PatientsAbeona Therapeutics, Inc · Epidermolysis BullosaActive, not recruitingABEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 9, 2022ActualPhase 1/Phase 2NCT01263379Gene Transfer for Recessive Dystrophic Epidermolysis BullosaAbeona Therapeutics, Inc · Epidermolysis Bullosa DystrophicaCompletedABEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 18, 2022ActualPhase 3NCT04227106Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Abeona Therapeutics, Inc · Epidermolysis BullosaCompletedABEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 7, 2022ActualNo phase registeredNCT04655911A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101Abeona Therapeutics, Inc · Mucopolysaccharidosis III-BTerminatedABEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 7, 2022ActualPhase 1/Phase 2NCT03315182Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIBAbeona Therapeutics, Inc · Mucopolysaccharidosis Type 3 BTerminatedABEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1996ActualPhase 3NCT00563433MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic UlcersAbeona Therapeutics, Inc · Diabetic Foot UlcersCompletedABEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1996ActualPhase 3NCT00563394MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic UlcersAbeona Therapeutics, Inc · Diabetic Foot UlcersCompletedABEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2008ActualPhase 2NCT00385502A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great ToenailAbeona Therapeutics, Inc · OnychomycosisCompletedABEOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimatePhase 2/Phase 3NCT02716246Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSHUltragenyx Pharmaceutical Inc · MPS IIIARecruitingRARELeadABEOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 10, 2022ActualPhase 1/Phase 2NCT04088734Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA DiseaseUltragenyx Pharmaceutical Inc · MPS IIIATerminatedRARELeadABEOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner